Bausch + Lomb Reports Phase 2 Results For BL1332; Primary Endpoint Missed, Exploratory Analyses Show Pain Relief And Faster Corneal Healing
Benzinga Newsdesk 1 day ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Both BL1332 doses demonstrated numerically greater pain relief than vehicle across all primary, secondary and exploratory pain analyses; the primary endpoint at 24 hours was not metExploratory analyses showed more
- Both BL1332 doses demonstrated numerically greater pain relief than vehicle across all primary, secondary and exploratory pain analyses; the primary endpoint at 24 hours was not met
- Exploratory analyses showed more patients achieved complete pain relief following surgery and faster corneal epithelium recovery when treated with BL1332
- Results support discussions with FDA regarding future development, including potential Phase 3 planning
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from a Phase 2 study evaluating BL1332, a first-in-class topical TRPV1 antagonist, in patients experiencing pain following photorefractive keratectomy (PRK) surgery.
More on BLCO
FDA & biotech Benzinga
Bausch + Lomb Post-Surgery Eye Pain Drug Misses Study Goal But Shows Early ReliefBausch + Lomb reports Phase 2 data for eye pain drug BL1332, showing early relief and strong safety despite missing its primary endpoint.

